Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel Free CARM Stock Alerts

Carisma Therapeutics (CARM) Competitors

Carisma Therapeutics logo
$0.0005 0.00 (0.00%)
As of 12:25 PM Eastern
Compare

CARM vs. EVGN, VINC, CDT, SISI, and SCPS

Should you buy Carisma Therapeutics stock or one of its competitors? Carisma Therapeutics's main competitors and comparable companies include Evogene (EVGN), Vincerx Pharma (VINC), CDT Equity (CDT), Shineco (SISI), and Scopus BioPharma (SCPS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Carisma Therapeutics compare to Evogene?

Evogene (NASDAQ:EVGN) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Evogene has higher earnings, but lower revenue than Carisma Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evogene$3.85M0.93-$8.48M-$0.91N/A
Carisma Therapeutics$10.77M0.00-$60.48M$0.730.00

Carisma Therapeutics has a net margin of -254.28% compared to Evogene's net margin of -694.18%. Carisma Therapeutics' return on equity of 0.00% beat Evogene's return on equity.

Company Net Margins Return on Equity Return on Assets
Evogene-694.18% -156.53% -86.80%
Carisma Therapeutics -254.28%N/A -192.17%

In the previous week, Evogene had 3 more articles in the media than Carisma Therapeutics. MarketBeat recorded 3 mentions for Evogene and 0 mentions for Carisma Therapeutics. Evogene's average media sentiment score of 0.13 beat Carisma Therapeutics' score of 0.00 indicating that Evogene is being referred to more favorably in the media.

Company Overall Sentiment
Evogene Neutral
Carisma Therapeutics Neutral

Evogene has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of -9.6, suggesting that its share price is 1,060% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evogene
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Carisma Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

10.4% of Evogene shares are held by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are held by institutional investors. 7.4% of Evogene shares are held by insiders. Comparatively, 6.9% of Carisma Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Evogene beats Carisma Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Carisma Therapeutics compare to Vincerx Pharma?

Carisma Therapeutics (NASDAQ:CARM) and Vincerx Pharma (NASDAQ:VINC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

In the previous week, Carisma Therapeutics' average media sentiment score of 0.00 equaled Vincerx Pharma'saverage media sentiment score.

Company Overall Sentiment
Carisma Therapeutics Neutral
Vincerx Pharma Neutral

44.3% of Carisma Therapeutics shares are held by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are held by institutional investors. 6.9% of Carisma Therapeutics shares are held by insiders. Comparatively, 15.6% of Vincerx Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Vincerx Pharma has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Carisma Therapeutics-254.28% N/A -192.17%
Vincerx Pharma N/A -248.33%-132.73%

Vincerx Pharma has lower revenue, but higher earnings than Carisma Therapeutics. Vincerx Pharma is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Carisma Therapeutics$10.77M0.00-$60.48M$0.730.00
Vincerx PharmaN/AN/A-$40.16M-$5.31N/A

Carisma Therapeutics has a beta of -9.6, indicating that its share price is 1,060% less volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market.

Summary

Carisma Therapeutics and Vincerx Pharma tied by winning 5 of the 10 factors compared between the two stocks.

How does Carisma Therapeutics compare to CDT Equity?

Carisma Therapeutics (NASDAQ:CARM) and CDT Equity (NASDAQ:CDT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

In the previous week, Carisma Therapeutics' average media sentiment score of 0.00 equaled CDT Equity'saverage media sentiment score.

Company Overall Sentiment
Carisma Therapeutics Neutral
CDT Equity Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Carisma Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
CDT Equity
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

CDT Equity has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat CDT Equity's return on equity.

Company Net Margins Return on Equity Return on Assets
Carisma Therapeutics-254.28% N/A -192.17%
CDT Equity N/A -72.25%-55.44%

Carisma Therapeutics has a beta of -9.6, indicating that its stock price is 1,060% less volatile than the broader market. Comparatively, CDT Equity has a beta of 1.59, indicating that its stock price is 59% more volatile than the broader market.

CDT Equity has lower revenue, but higher earnings than Carisma Therapeutics. CDT Equity is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Carisma Therapeutics$10.77M0.00-$60.48M$0.730.00
CDT EquityN/AN/A-$39.22M-$83.86 thousandN/A

44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 3.3% of CDT Equity shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by company insiders. Comparatively, 7.3% of CDT Equity shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

CDT Equity beats Carisma Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Carisma Therapeutics compare to Shineco?

Carisma Therapeutics (NASDAQ:CARM) and Shineco (NASDAQ:SISI) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

In the previous week, Shineco had 2 more articles in the media than Carisma Therapeutics. MarketBeat recorded 2 mentions for Shineco and 0 mentions for Carisma Therapeutics. Carisma Therapeutics' average media sentiment score of 0.00 equaled Shineco'saverage media sentiment score.

Company Overall Sentiment
Carisma Therapeutics Neutral
Shineco Neutral

44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 4.1% of Shineco shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by company insiders. Comparatively, 0.0% of Shineco shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Carisma Therapeutics has a beta of -9.6, meaning that its share price is 1,060% less volatile than the broader market. Comparatively, Shineco has a beta of -1.76, meaning that its share price is 276% less volatile than the broader market.

Shineco has lower revenue, but higher earnings than Carisma Therapeutics. Shineco is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Carisma Therapeutics$10.77M0.00-$60.48M$0.730.00
Shineco$9.60M0.00-$22.45M-$204.00N/A

Carisma Therapeutics has a net margin of -254.28% compared to Shineco's net margin of -380.55%. Carisma Therapeutics' return on equity of 0.00% beat Shineco's return on equity.

Company Net Margins Return on Equity Return on Assets
Carisma Therapeutics-254.28% N/A -192.17%
Shineco -380.55%-79.89%-33.01%

Summary

Carisma Therapeutics beats Shineco on 7 of the 12 factors compared between the two stocks.

How does Carisma Therapeutics compare to Scopus BioPharma?

Carisma Therapeutics (NASDAQ:CARM) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Scopus BioPharma has lower revenue, but higher earnings than Carisma Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Carisma Therapeutics$10.77M0.00-$60.48M$0.730.00
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

In the previous week, Carisma Therapeutics' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company Overall Sentiment
Carisma Therapeutics Neutral
Scopus BioPharma Neutral

Carisma Therapeutics has a beta of -9.6, meaning that its share price is 1,060% less volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.32, meaning that its share price is 132% less volatile than the broader market.

44.3% of Carisma Therapeutics shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Scopus BioPharma has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%.

Company Net Margins Return on Equity Return on Assets
Carisma Therapeutics-254.28% N/A -192.17%
Scopus BioPharma N/A N/A N/A

Summary

Scopus BioPharma beats Carisma Therapeutics on 4 of the 7 factors compared between the two stocks.

Get Carisma Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CARM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CARM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CARM vs. The Competition

Export
MetricCarisma TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$21K$12.25B$7.14B$13.21B
Dividend YieldN/A2.65%2.53%16.47%
P/E Ratio0.00802.39275.1525.94
Price / Sales0.00747.53566.7884.28
Price / CashN/A86.0477.4152.81
Price / Book0.0010.6610.806.27
Net Income-$60.48M$2.83B$3.50B$382.13M
7 Day PerformanceN/A-1.62%-2.02%-1.35%
1 Month PerformanceN/A-7.65%-7.53%-5.60%
1 Year PerformanceN/A-6.26%3.32%-1.54%

Carisma Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CARM
Carisma Therapeutics
N/A$0.00
flat		N/A-99.8%$21K$10.77M0.0020
EVGN
Evogene
1.3066 of 5 stars		$0.41
+7.9%		N/A-69.1%$3.31M$3.85MN/A52
VINC
Vincerx Pharma
N/A$0.02
flat		N/A-76.9%$79KN/AN/A60
CDT
CDT Equity
N/A$1.45
-23.7%		N/A-100.0%$60KN/AN/A4
SISI
Shineco
N/A$0.11
flat		N/AN/A$44K$9.60MN/A119

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CARM) was last updated on 10/8/2026 by MarketBeat.com Staff.
From Our Partners
The national debt just passed $39 trillion
The U.S. national debt just topped $39 trillion, up nearly $3 trillion in a single year and on pace to hit $40...
US Gold Bureau | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
"The largest market in human history"
SpaceX quietly filed paperwork describing what it calls the largest actionable total addressable market in hum...
Behind the Markets | Sponsoredtc pixel
$169 Private Jet Trick Exposed
For $169, a growing circle of travelers are booking private jets without the wait, the hassle, or the high pri...
International Living | Sponsoredtc pixel
A simple options setup that cuts through the noise
Ian Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...
TradeWins | Sponsoredtc pixel
This free guide explains options the way they should be taught
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...
Base Camp Trading | Sponsoredtc pixel